Teamwork Financial Advisors LLC Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Teamwork Financial Advisors LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 73.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,717 shares of the pharmaceutical company’s stock after selling 7,378 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,094,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $27,000. Dunhill Financial LLC raised its holdings in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the last quarter. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at $33,000. Finally, Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $35,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on VRTX shares. Bank of America reduced their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Barclays decreased their target price on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research note on Friday, December 20th. Stifel Nicolaus raised their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday, January 13th. Finally, BMO Capital Markets cut their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research note on Friday, December 20th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Stock Up 0.0 %

VRTX stock opened at $428.00 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a market cap of $110.22 billion, a PE ratio of -215.08, a PEG ratio of 2.20 and a beta of 0.40. The firm’s 50 day moving average price is $436.77 and its 200-day moving average price is $465.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the prior year, the company posted $3.67 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.